177858-80-9

Basic information

• Product Name: 7-Fluoro-2,3,4,9-tetrahydro-1H-beta-carboline, 95+%
• Synonyms: 7-Fluoro-2,3,4,9-tetrahydro-1H-beta-carboline, 95+%
• CAS NO: 177858-80-9
• Molecular Formula: C₁₁H₁₁FN₂
• Molecular Weight: 190
• Mol File: 177858-80-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 216-224℃
• Appearance: /
• CAS DataBase Reference: 7-Fluoro-2,3,4,9-tetrahydro-1H-beta-carboline, 95+%(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Fluoro-2,3,4,9-tetrahydro-1H-beta-carboline, 95+%(177858-80-9)
• EPA Substance Registry System: 7-Fluoro-2,3,4,9-tetrahydro-1H-beta-carboline, 95+%(177858-80-9)

Safety Data

• Hazardous Substances Data: 177858-80-9(Hazardous Substances Data)

Upstream product

• 783349-33-7 7-fluoro-2,3,4,9-tetrahydro-1H-β-carboline-1-carboxylic acid 
• 575-85-9 6-fluorotryptamine 
• 298-12-4 Glyoxilic acid 
• 399-51-9 6-fluoro-1H-indole 
• 50-00-0 formaldehyd 
• 55206-24-1 2-(6-fluoro-1H-indol-3-yl)ethan-1 -amine hydrochloride 

Downstream Products

• 1288977-51-4 (1S,2R,3R)-1-(7-fluoro-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-2-sulfonylamino)-2-methyl-3-phenylcyclopropane-1-carboxylic acid 

Relevant articles and documents

Catalytic Enantioselective Synthesis of Spirooxindoles by Oxidative Rearrangement of Indoles

Oxidative rearrangement of indoles to access oxindoles has been used as a key step in complex molecule synthesis. We report a catalytic enantioselective variant of this transformation by chiral phosphoric acid catalysis, providing rapid access to a range of enantioenriched spirooxindoles. The high enantioselectivity is controlled by dynamic kinetic resolution.

INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:

BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE

This invention provides beta-carboline compounds of formula (I) wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R1, R2 and R3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2 mediated diseases such as inflammatory diseases and cancer.